Non-small cell lung cancer, Version 2.2021 featured updates to the NCCN guidelines: Non-Small Cell Lung Cancer, Version 2.2021

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Matthew A. Gubens, Aparna Hegde, Mark Hennon, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules LinBilly W. Loo, Christine M. Lovly, Renato G. Martins, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Jane Yanagawa, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes

Research output: Contribution to journalReview articlepeer-review

736 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.

Original languageEnglish
Pages (from-to)254-266
Number of pages13
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume19
Issue number3
DOIs
StatePublished - Mar 2021

Keywords

  • Biomarkers, Tumor
  • Carcinoma, Non-Small-Cell Lung/diagnosis
  • Humans
  • Immunotherapy
  • Lung Neoplasms/diagnosis

Fingerprint

Dive into the research topics of 'Non-small cell lung cancer, Version 2.2021 featured updates to the NCCN guidelines: Non-Small Cell Lung Cancer, Version 2.2021'. Together they form a unique fingerprint.

Cite this